Novo Nordisk’s diabetes drug Ozempic reduces the risk of kidney failure and death in patients who have both Type 2 diabetes and chronic kidney disease, according to new research published Friday.

Semaglutide, the compound in the blockbuster drugs Ozempic and Wegovy, dramatically reduced the risk of kidney complications, heart issues and death in people with Type 2 diabetes and chronic ...

N ovo Nordisk’s Ozempic cut the risk of death in a trial of patients with type 2 diabetes and chronic kidney disease, suggesting it may offer some added benefits over other classes of drugs ...

The Food and Drug Administration on Tuesday approved Novo Nordisk 's Ozempic to treat chronic kidney disease in patients who also have Type 2 diabetes, expanding the use of the wildly popular ...

The Food and Drug Administration approved Novo Nordisk's Ozempic for patients with both chronic kidney disease and diabetes, expanding the use of the wildly popular injection in the U.S.

Novo Nordisk ’s Ozempic drug slows the progression of chronic kidney disease and cuts the risk of kidney failure, heart attack, stroke and death in patients with Type 2 diabetes, detailed ...

"All chronic kidney disease is progressive. It's a year-on-year, relentless decline in renal function," Stephen Gough, Novo Nordisk's global chief medical officer, said in an interview, referring ...